(S)-α-ethoxy-4-[2-[-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]benzenepropanoic acid potassium salt | 1392592-60-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: (S)-α-ethoxy-4-[2-[-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]benzenepropanoic acid potassium salt
• 英文别名: (S)-2-ethoxy-3-(4-{2-[2-methyl-5-(4-(methylthio)phenyl)pyrrol-1-yl]ethoxy}phenyl)propionic acid potassium salt；(S)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoic acid potassium salt；(S)-alpha-ethoxy-4-[2-[-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]benzenepropanoic acid potassium salt；potassium;(2S)-2-ethoxy-3-[4-[2-[2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl]ethoxy]phenyl]propanoate
• CAS: 1392592-60-7
• 化学式: C₂₅H₂₈NO₄S*K
• 分子量: 477.666
• InChiKey: VKEZRUXOXRXGNR-JIDHJSLPSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.97
• 重原子数：
  32
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  88.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (S)-α-ethoxy-4-[2-[-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]benzenepropanoic acid magnesium salt 在 盐酸 、 potassium tert-butylate 、 水 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 0.5h， 生成 (S)-α-ethoxy-4-[2-[-methyl-5-[4-(methylthio)phenyl]-1H-pyrrol-1-yl]ethoxy]benzenepropanoic acid potassium salt
  参考文献：
  名称：

  [EN] SYNERGISTIC COMPOSITIONS
  [FR] COMPOSITIONS SYNERGIQUES

  摘要：

  公开号：

  WO2015001573A9

文献信息

• [EN] NOVEL SALTS, CRYSTALLINE FORMS AND PREMIX OF HYPOLIPIDEMIC AGENT<br/>[FR] NOUVEAUX SELS, FORMES CRISTALLINES ET PRÉMÉLANGE D'AGENT HYPOLIPIDÉMIQUE
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2020183379A1

  公开（公告）日：2020-09-17

  Present invention relates to novel salts of saroglitazar and certain polymorphic forms of saroglitazar salts. Invention provides process for the preparation of novel salts and polymorphic forms of saroglitazar. Invention also provides novel co-precipitants or premixes of saroglitazar with pharmaceutically acceptable excipients/secondary therapeutic agent and process for the preparing same.

  本发明涉及萨罗格利他新型盐和某些萨罗格利他盐的多晶形式。本发明提供了制备新型盐和多晶形式的方法。本发明还提供了萨罗格利他与药学上可接受的辅料/次级治疗剂的新型共沉淀剂或预混合物，以及其制备方法。
• TREATMENT FOR LIPODYSTROPHY
  申请人：Gambhire Dhiraj

  公开号：US20130338209A1

  公开（公告）日：2013-12-19

  The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (Pis) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.

  本发明提供了一种治疗化合物(I)及其在预防和治疗因HIV感染或HIV-1蛋白酶抑制剂（Pis）和/或逆转录酶抑制剂（nRTIs）联合治疗引起的脂肪萎缩症的药物可接受盐，通过中和HIV患者的脂肪肥大、脂肪萎缩和代谢异常。
• SYNERGISTIC COMPOSITIONS
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20160068484A1

  公开（公告）日：2016-03-10

  The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I): processes for the preparation of these novel salts and use thereof.

  本发明涉及一种协同作用组合物，包括一种或多种他汀类药物、一种或多种二肽基肽酶IV（DPP IV）抑制剂或一种或多种双胍类降糖药物以及一种公式（Ia）的PPAR激动剂，用于治疗糖尿病，特别是非胰岛素依赖性糖尿病（NIDDM）或2型糖尿病以及与糖尿病相关的疾病，以及适用于此类方法的组合物。本发明还描述了这种组合物的制备方法。本发明还涉及公式（I）的PPAR激动剂的某些新型盐：制备这些新型盐的方法及其用途。
• Synergistic compositions
  申请人：Cadila Healthcare Limited

  公开号：US10315993B2

  公开（公告）日：2019-06-11

  The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of these novel salts and use thereof.

  本发明描述了一种由一种或多种他汀类药物，或一种或多种二肽基肽酶 IV (DPP IV) 抑制剂，或一种或多种双胍类抗高血糖药和式（Ia）的 PPAR 激动剂组成的协同组合物，用于治疗糖尿病，特别是非胰岛素依赖型糖尿病（NIDDM）或 2 型糖尿病以及与糖尿病相关的病症，并描述了适用于这种方法的组合物。本发明还描述了此类组合物的制备方法。本发明还涉及式（I）PPAR 激动剂的某些新型盐、制备这些新型盐的工艺及其用途。
• NOVEL SALTS, CRYSTALLINE FORMS AND PREMIX OF HYPOLIPIDEMIC AGENT
  申请人：Cadila Healthcare Ltd.

  公开号：US20220169603A1

  公开（公告）日：2022-06-02

  Present invention relates to novel salts of saroglitazar and certain polymorphic forms of saroglitazar salts. Invention provides process for the preparation of novel salts and polymorphic forms of saroglitazar. Invention also provides novel co-precipitants or premixes of saroglitazar with pharmaceutically acceptable excipients/secondary therapeutic agent and process for the preparing same.